LTPA2022525I1 - - Google Patents
Info
- Publication number
- LTPA2022525I1 LTPA2022525I1 LTPA2022525C LTPA2022525C LTPA2022525I1 LT PA2022525 I1 LTPA2022525 I1 LT PA2022525I1 LT PA2022525 C LTPA2022525 C LT PA2022525C LT PA2022525 C LTPA2022525 C LT PA2022525C LT PA2022525 I1 LTPA2022525 I1 LT PA2022525I1
- Authority
- LT
- Lithuania
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07301435A EP2058401A1 (en) | 2007-10-05 | 2007-10-05 | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
PCT/EP2008/063297 WO2009043936A1 (en) | 2007-10-05 | 2008-10-03 | Widespread gene delivery to motor neurons using peripheral injection of aav vectors |
EP08836776.8A EP2212424B2 (en) | 2007-10-05 | 2008-10-03 | Widespread gene delivery to motor neurons using peripheral injection of aav vectors |
EP12180951.1A EP2527457B1 (en) | 2007-10-05 | 2008-10-03 | Widespread gene delivery to motor neurons using peripheral injection of aav vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
LTPA2022525I1 true LTPA2022525I1 (lt) | 2022-12-12 |
Family
ID=39186802
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP19158152.9T LT3505635T (lt) | 2007-10-05 | 2008-10-03 | Platus genų perdavimas motoriniams neuronams naudojant periferinę aav vektorių injekciją |
LTPA2022525C LTPA2022525I1 (lt) | 2007-10-05 | 2022-11-16 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP19158152.9T LT3505635T (lt) | 2007-10-05 | 2008-10-03 | Platus genų perdavimas motoriniams neuronams naudojant periferinę aav vektorių injekciją |
Country Status (18)
Country | Link |
---|---|
US (3) | US9926574B2 (lt) |
EP (5) | EP2058401A1 (lt) |
JP (2) | JP5620819B2 (lt) |
CN (2) | CN105087650A (lt) |
CA (2) | CA2701561C (lt) |
CY (1) | CY1125608T1 (lt) |
DK (2) | DK2212424T3 (lt) |
ES (3) | ES2924892T3 (lt) |
FI (1) | FI2212424T4 (lt) |
FR (2) | FR20C1057I2 (lt) |
HR (2) | HRP20220992T3 (lt) |
HU (2) | HUE059864T2 (lt) |
LT (2) | LT3505635T (lt) |
NO (1) | NO2022048I1 (lt) |
PL (2) | PL3505635T3 (lt) |
PT (3) | PT2212424E (lt) |
SI (2) | SI3505635T1 (lt) |
WO (1) | WO2009043936A1 (lt) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120322861A1 (en) | 2007-02-23 | 2012-12-20 | Barry John Byrne | Compositions and Methods for Treating Diseases |
EP2019143A1 (en) * | 2007-07-23 | 2009-01-28 | Genethon | CNS gene delivery using peripheral administration of AAV vectors |
EP2058401A1 (en) * | 2007-10-05 | 2009-05-13 | Genethon | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
EP4160212B1 (en) | 2008-01-15 | 2024-04-17 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
US9415121B2 (en) | 2008-12-19 | 2016-08-16 | Nationwide Children's Hospital | Delivery of MECP2 polynucleotide using recombinant AAV9 |
US11219696B2 (en) | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
JP5879256B2 (ja) * | 2009-05-02 | 2016-03-08 | ジェンザイム・コーポレーション | 神経変性障害のための遺伝子治療 |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
DK2561073T3 (en) * | 2010-04-23 | 2016-12-12 | Univ Massachusetts | Aav vectors targeted to central nervous system and methods of use thereof |
CA2833905C (en) | 2010-04-23 | 2019-09-10 | University Of Massachusetts | Multicistronic expression constructs |
EP2561075B1 (en) | 2010-04-23 | 2018-06-27 | University of Massachusetts | Aav-based treatment of cholesterol-related disorders |
CN103189507A (zh) * | 2010-10-27 | 2013-07-03 | 学校法人自治医科大学 | 用于向神经系统细胞导入基因的腺相关病毒粒子 |
ES2661680T3 (es) | 2011-04-21 | 2018-04-03 | University Of Massachusetts | Composiciones basadas en VAAr y métodos para tratar deficiencias de alfa-1 anti-tripsina |
US20130039888A1 (en) * | 2011-06-08 | 2013-02-14 | Nationwide Children's Hospital Inc. | Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders |
AU2013277215A1 (en) * | 2012-06-19 | 2015-02-05 | University Of Florida Research Foundation, Inc. | Compositions and methods for treating diseases |
EP3536795A3 (en) | 2012-06-21 | 2019-12-11 | Association Institut de Myologie | Widespread gene expression |
US20150252384A1 (en) | 2012-08-01 | 2015-09-10 | National Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
CA2885216A1 (en) | 2012-09-17 | 2014-03-20 | The Research Institute At Nationwide Children's Hospital | Compositions and methods for treating amyotrophic lateral sclerosis |
CA3209821A1 (en) * | 2013-05-15 | 2014-11-20 | Regents Of The University Of Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
PT3039146T (pt) | 2013-08-27 | 2020-08-11 | The Res Institute At Nationwide Childrens Hospital | Produtos e métodos para tratamento de esclerose lateral amiotrófica |
CA2929669A1 (en) | 2013-11-05 | 2015-05-14 | The Research Institute At Nationwide Children's Hospital | Compositions and methods for inhibiting nf-.kappa.b and sod-1 to treat amyotrophic lateral sclerosis |
BR112016020688B1 (pt) * | 2014-03-09 | 2024-01-30 | The Trustees Of The University Of Pennsylvania | Vetores virais recombinantes, vírus adenoassociado recombinante, composição farmacêutica, bem como uso dos mesmos |
EP2933335A1 (en) * | 2014-04-18 | 2015-10-21 | Genethon | A method of treating peripheral neuropathies and motor neuron diseases |
WO2015187825A2 (en) | 2014-06-03 | 2015-12-10 | University Of Massachusetts | Compositions and methods for modulating dysferlin expression |
CA2955285C (en) | 2014-07-31 | 2023-09-26 | Association Institut De Myologie | Treatment of amyotrophic lateral sclerosis |
JP6842410B2 (ja) | 2014-10-03 | 2021-03-17 | ユニバーシティ オブ マサチューセッツ | 新規の高効率ライブラリーにより同定されるaavベクター |
US10370432B2 (en) | 2014-10-03 | 2019-08-06 | University Of Massachusetts | Heterologous targeting peptide grafted AAVS |
JP7023108B2 (ja) | 2014-10-21 | 2022-02-21 | ユニバーシティ オブ マサチューセッツ | 組み換えaavバリアントおよびその使用 |
CN114717264A (zh) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
EP3221453A4 (en) | 2014-11-21 | 2018-09-12 | The University of North Carolina at Chapel Hill | Aav vectors targeted to the central nervous system |
AU2015364636B9 (en) | 2014-12-16 | 2021-12-02 | Board Of Regents Of The University Of Nebraska | Gene therapy for Juvenile Batten Disease |
WO2016131009A1 (en) | 2015-02-13 | 2016-08-18 | University Of Massachusetts | Compositions and methods for transient delivery of nucleases |
US20180104289A1 (en) * | 2015-04-08 | 2018-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Viral gene therapy as treatment for cholesterol storage disease or disorder |
WO2016172008A1 (en) | 2015-04-24 | 2016-10-27 | University Of Massachusetts | Modified aav constructions and uses thereof |
AU2016332847B2 (en) * | 2015-10-01 | 2023-08-10 | Goleini Inc. | Targeted expression of chloride channels and methods of use thereof |
WO2017070472A1 (en) * | 2015-10-21 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Codon-optimized reduced-size atp7a cdna and uses for treatment of copper transport disorders |
CA3002980A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Prostate-targeting adeno-associated virus serotype vectors |
CA3002982A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance in neurodegenerative disease |
US20180230489A1 (en) | 2015-10-28 | 2018-08-16 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
EP3411059A4 (en) | 2016-02-02 | 2019-10-16 | University Of Massachusetts | METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM |
EP4094780A3 (en) | 2016-02-12 | 2023-02-08 | University of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
WO2017176929A1 (en) | 2016-04-05 | 2017-10-12 | University Of Massachusetts | Compositions and methods for selective inhibition of grainyhead-like protein expression |
US11253612B2 (en) | 2016-04-15 | 2022-02-22 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type II |
US11413356B2 (en) | 2016-04-15 | 2022-08-16 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance |
AU2017284198B2 (en) | 2016-06-13 | 2023-09-28 | The University Of North Carolina At Chapel Hill | Optimized CLN1 genes and expression cassettes and their use |
WO2017218852A1 (en) | 2016-06-15 | 2017-12-21 | University Of Massachusetts | Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells |
US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
AU2017341849B2 (en) | 2016-10-13 | 2024-03-21 | University Of Massachusetts | AAV capsid designs |
CN108524952A (zh) * | 2017-03-06 | 2018-09-14 | 复旦大学 | 腺相关病毒aav9及其在制备治疗戈谢氏病的制剂中的用途 |
AU2018261790A1 (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
CN111132626B (zh) | 2017-07-17 | 2024-01-30 | 沃雅戈治疗公司 | 轨迹阵列引导系统 |
JP7221275B2 (ja) | 2017-08-03 | 2023-02-13 | ボイジャー セラピューティクス インコーポレイテッド | Aavを送達するための組成物および方法 |
SG11202002457RA (en) | 2017-09-22 | 2020-04-29 | Univ Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
US11434502B2 (en) | 2017-10-16 | 2022-09-06 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (ALS) |
CA3082136A1 (en) * | 2017-11-08 | 2019-05-16 | Avexis, Inc. | Means and method for preparing viral vectors and uses of same |
US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
JP7244547B2 (ja) | 2018-02-19 | 2023-03-22 | ホモロジー・メディシンズ・インコーポレイテッド | F8遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法 |
TW202015742A (zh) | 2018-05-15 | 2020-05-01 | 美商航海家醫療公司 | 投遞腺相關病毒(aav)之組成物和方法 |
CN112424359A (zh) | 2018-05-15 | 2021-02-26 | 沃雅戈治疗公司 | 用于治疗帕金森氏病的组合物和方法 |
US20210214749A1 (en) | 2018-05-16 | 2021-07-15 | Voyager Therapeutics, Inc. | Directed evolution |
WO2020010035A1 (en) | 2018-07-02 | 2020-01-09 | Voyager Therapeutics, Inc. | Cannula system |
CA3103963A1 (en) | 2018-07-02 | 2020-01-09 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
US20210355454A1 (en) | 2018-07-24 | 2021-11-18 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
WO2020072849A1 (en) | 2018-10-04 | 2020-04-09 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
US20210371470A1 (en) | 2018-10-12 | 2021-12-02 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
JP2022522995A (ja) | 2019-01-18 | 2022-04-21 | ボイジャー セラピューティクス インコーポレイテッド | Aav粒子を生成するための方法及びシステム |
CA3127019A1 (en) * | 2019-02-05 | 2020-08-13 | The Trustees Of Princeton University | Recombinant nucleic acids containing alphaherpesvirus promoter sequences |
CN109706176A (zh) * | 2019-03-12 | 2019-05-03 | 青岛大学附属医院 | 可靶向转染背根神经节卫星胶质细胞腺病毒载体构建方法 |
WO2020198737A1 (en) * | 2019-03-28 | 2020-10-01 | The General Hospital Corporation | Engineered adeno-associated (aav) vectors for transgene expression |
AU2020336332A1 (en) * | 2019-08-29 | 2022-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Adeno-associated viral vectors for crossing the human blood brain barrier |
WO2021046155A1 (en) | 2019-09-03 | 2021-03-11 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
CN114787180A (zh) | 2019-10-17 | 2022-07-22 | 斯特里迪比奥公司 | 用于治疗c型尼曼-匹克病的腺相关病毒载体 |
TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
CA3180222A1 (en) | 2020-04-15 | 2021-10-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
PE20230767A1 (es) | 2020-05-13 | 2023-05-09 | Voyager Therapeutics Inc | Redireccion del tropismo de las capsides de aav |
CN112121179A (zh) * | 2020-09-15 | 2020-12-25 | 山东兴瑞生物科技有限公司 | 一种组合物及其在治疗脊髓性肌萎缩症中的应用 |
WO2022187548A1 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
CN115708866A (zh) * | 2021-08-23 | 2023-02-24 | 中国科学院深圳先进技术研究院 | 骨源因子rankl在制备调控中枢神经系统稳态的药物或药物组合物中的应用 |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
TW202334436A (zh) | 2021-11-02 | 2023-09-01 | 美商航海家醫療公司 | Aav衣殼變異體及其用途 |
TW202334181A (zh) | 2021-11-17 | 2023-09-01 | 美商航海家醫療公司 | Aav蛋白殼變異體及其用途 |
TW202346599A (zh) | 2022-02-08 | 2023-12-01 | 美商航海家醫療公司 | Aav衣殼變異體及其用途 |
WO2023235791A1 (en) | 2022-06-02 | 2023-12-07 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024006741A1 (en) | 2022-06-28 | 2024-01-04 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024011112A1 (en) | 2022-07-06 | 2024-01-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
CN116064671A (zh) * | 2022-08-10 | 2023-05-05 | 深圳先进技术研究院 | 一种基因递送系统将基因递送到小胶质细胞的应用 |
WO2024059739A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0832266A4 (en) | 1995-06-07 | 2000-06-28 | Univ Yale | ORAL ADMINISTRATION OF VECTORS OF VENUS ASSOCIATED WITH ADENOVIRUS |
US20040076613A1 (en) | 2000-11-03 | 2004-04-22 | Nicholas Mazarakis | Vector system |
FR2756297B1 (fr) | 1996-11-22 | 1999-01-08 | Centre Nat Rech Scient | Procede de production de virus recombinants |
JP2001512142A (ja) | 1997-07-31 | 2001-08-21 | カイロン コーポレイション | 宿主の免疫抑制を介するaavベクターの再投与を可能にする方法 |
CA2348382C (en) | 1998-11-10 | 2013-09-17 | The University Of North Carolina At Chapel Hill | Chimeric parvovirus vectors and methods of making and administering the same |
US6498244B1 (en) | 1999-05-28 | 2002-12-24 | Cell Genesys, Inc. | Adeno-associated virus capsid immunologic determinants |
JP2003523320A (ja) | 1999-09-29 | 2003-08-05 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ウイルスベクターの迅速なpeg改変方法、高められた遺伝子形質導入のための組成物、高められた物理的安定性を伴う組成物、およびそのための用途 |
WO2001036603A2 (en) | 1999-11-17 | 2001-05-25 | Avigen, Inc. | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
WO2001091803A2 (en) | 2000-06-01 | 2001-12-06 | University Of North Carolina At Chapel Hill | Methods and compounds for controlled release of recombinant parvovirus vectors |
AU2001269723B9 (en) * | 2000-06-01 | 2006-11-16 | University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
EP1402043A1 (en) | 2001-07-03 | 2004-03-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods of administering vectors to synaptically connected neurons |
NZ578982A (en) * | 2001-11-13 | 2011-03-31 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
EP3339430A1 (en) | 2001-12-17 | 2018-06-27 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses thereof |
EP1463530A4 (en) | 2001-12-19 | 2006-09-06 | Lijun Wang | ADENO-ASSOCIATED VIRUS-RELATED DELIVERY OF GDNF TO SKELETAL MUSCLES |
US6998118B2 (en) * | 2001-12-21 | 2006-02-14 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery for neuronal protection |
NZ533833A (en) | 2001-12-21 | 2008-01-31 | Salk Inst For Biological Studi | Targeted retrograde gene delivery to motor neurons |
WO2006002283A1 (en) * | 2004-06-21 | 2006-01-05 | Medtronic, Inc. | Medical systems and methods for delivering compositions to cells |
JP2007524379A (ja) * | 2003-03-31 | 2007-08-30 | ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン | 上皮ナトリウムチャンネル関連障害のPharmico−遺伝子治療 |
CA2527907A1 (en) * | 2003-06-03 | 2004-12-09 | Benitec Australia Limited | Double-stranded hairpin rnas for rnai |
PT3235827T (pt) | 2003-06-19 | 2021-04-09 | Genzyme Corp | Viriões aav com imunorreatividade diminuída e seus usos |
US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
EP3910063A1 (en) | 2003-09-30 | 2021-11-17 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
AU2004281764B2 (en) * | 2003-10-14 | 2011-04-07 | Neurologix Research, Inc. | Methods and compositions for the treatment of neurological disease |
US8734810B2 (en) | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
WO2005056807A2 (en) | 2003-12-04 | 2005-06-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health | Bovine adeno-associated viral (baav) vector and uses thereof |
WO2005072364A2 (en) | 2004-01-27 | 2005-08-11 | University Of Florida | A modified baculovirus expression system for production of pseudotyped raav vector |
EP1732383A4 (en) * | 2004-04-06 | 2007-05-02 | Cedars Sinai Medical Center | PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH VIRUS VECTORS ASSOCIATED WITH RECOMBINANT ADENOVIRUS CODING APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO |
US20060110364A1 (en) * | 2004-08-20 | 2006-05-25 | Ludwig Institute For Cancer Research | Vector-mediated delivery of polynucleotides encoding soluble VEGF receptors |
WO2006119432A2 (en) | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
CA2606490C (en) | 2005-05-02 | 2018-02-06 | Genzyme Corporation | Gene therapy for spinal cord disorders |
WO2007089632A2 (en) * | 2006-01-27 | 2007-08-09 | The University Of North Carolina At Chapel Hill | Heparin and heparan sulfate binding chimeric vectors |
US20070280906A1 (en) | 2006-06-03 | 2007-12-06 | Ognjen Petras | Method to generate mirrored adenoassociated viral vectors |
US20100221225A1 (en) * | 2007-02-23 | 2010-09-02 | University Of Florida Research Foundation, Inc | Compositions and methods for treating glycogen storage diseases |
US10696983B2 (en) | 2007-05-30 | 2020-06-30 | The Trustees Of The University Of Pennsylvania | Method for transducing cells with primary cilia |
EP2019143A1 (en) | 2007-07-23 | 2009-01-28 | Genethon | CNS gene delivery using peripheral administration of AAV vectors |
US20090087413A1 (en) | 2007-10-01 | 2009-04-02 | Alcon Research, Ltd. | Self-complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders |
EP2058401A1 (en) * | 2007-10-05 | 2009-05-13 | Genethon | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
US11219696B2 (en) * | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
-
2007
- 2007-10-05 EP EP07301435A patent/EP2058401A1/en not_active Withdrawn
-
2008
- 2008-10-03 EP EP21161090.2A patent/EP3854878A1/en active Pending
- 2008-10-03 ES ES19158152T patent/ES2924892T3/es active Active
- 2008-10-03 DK DK08836776.8T patent/DK2212424T3/da active
- 2008-10-03 HR HRP20220992TT patent/HRP20220992T3/hr unknown
- 2008-10-03 LT LTEP19158152.9T patent/LT3505635T/lt unknown
- 2008-10-03 US US12/734,016 patent/US9926574B2/en active Active
- 2008-10-03 EP EP08836776.8A patent/EP2212424B2/en active Active
- 2008-10-03 PT PT88367768T patent/PT2212424E/pt unknown
- 2008-10-03 PT PT191581529T patent/PT3505635T/pt unknown
- 2008-10-03 SI SI200832199T patent/SI3505635T1/sl unknown
- 2008-10-03 EP EP19158152.9A patent/EP3505635B1/en active Active
- 2008-10-03 ES ES08836776.8T patent/ES2482094T3/es active Active
- 2008-10-03 SI SI200831238T patent/SI2212424T1/sl unknown
- 2008-10-03 CN CN201510438197.1A patent/CN105087650A/zh active Pending
- 2008-10-03 CA CA2701561A patent/CA2701561C/en active Active
- 2008-10-03 PT PT12180951T patent/PT2527457T/pt unknown
- 2008-10-03 HU HUE19158152A patent/HUE059864T2/hu unknown
- 2008-10-03 CA CA2999607A patent/CA2999607A1/en not_active Abandoned
- 2008-10-03 CN CN2008801174130A patent/CN101883859A/zh active Pending
- 2008-10-03 EP EP12180951.1A patent/EP2527457B1/en not_active Revoked
- 2008-10-03 PL PL19158152.9T patent/PL3505635T3/pl unknown
- 2008-10-03 WO PCT/EP2008/063297 patent/WO2009043936A1/en active Application Filing
- 2008-10-03 PL PL08836776T patent/PL2212424T3/pl unknown
- 2008-10-03 JP JP2010527467A patent/JP5620819B2/ja active Active
- 2008-10-03 ES ES12180951T patent/ES2727034T3/es active Active
- 2008-10-03 DK DK19158152.9T patent/DK3505635T3/da active
-
2014
- 2014-07-01 JP JP2014136031A patent/JP6309373B2/ja active Active
- 2014-07-07 HR HRP20140643AT patent/HRP20140643T1/hr unknown
-
2017
- 2017-09-22 US US15/713,347 patent/US20180066283A1/en active Pending
-
2019
- 2019-08-09 US US16/536,503 patent/US11767538B2/en active Active
-
2020
- 2020-11-17 FI FIEP08836776.8T patent/FI2212424T4/fi active
- 2020-11-17 FR FR20C1057C patent/FR20C1057I2/fr active Active
-
2022
- 2022-08-16 CY CY20221100551T patent/CY1125608T1/el unknown
- 2022-11-16 NO NO2022048C patent/NO2022048I1/no unknown
- 2022-11-16 HU HUS2200047C patent/HUS2200047I1/hu unknown
- 2022-11-16 LT LTPA2022525C patent/LTPA2022525I1/lt unknown
- 2022-11-17 FR FR22C1056C patent/FR22C1056I1/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTPA2022525I1 (lt) | ||
CN104335712B8 (lt) | ||
CN300731847S (zh) | 工具(多功能套装) | |
CN300726257S (zh) | 墙纸(11) | |
CN300731844S (zh) | 热风枪(8624) | |
CN300728305S (zh) | 型材(pm9898) | |
CN300728125S (zh) | 刀(武士刀ss030) | |
CN300728345S (zh) | 金属探测自控门(2007b) | |
CN300727777S (zh) | 数控雕铣机床 | |
CN300727578S (zh) | 收音机(e-1010) | |
CN300726928S (zh) | 包装盒(盐酸布替萘芬软膏) | |
CN300726325S (zh) | 椅子(2101) | |
CN300882855S (zh) | 纸巾包装袋(钱包式) | |
CN300876938S (zh) | 复合片(四) | |
CN300839146S (zh) | 计算机显示终端主机 | |
CN300779959S (zh) | 袜子(newhongda-019) | |
CN300778910S (zh) | 双筒望远镜(mh2100ⅲ) | |
CN300776589S (zh) | 门窗型材(b) | |
CN300772661S (zh) | 汽车发电机(20) | |
CN300734533S (zh) | 真皮沙发(a766#) | |
CN300734229S (zh) | 手帕 | |
CN300733791S (zh) | 手提灯 | |
CN300733579S (zh) | 移液器架 | |
CN300733231S (zh) | 标贴(火锅午餐肉) | |
CN300733122S (zh) | 橡皮(k-0712) |